Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab in Severe Pulmonary COVID-19
NCT04376684Phase 2Completed
- Sponsor
- GSK
- Start
- May 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of otilimab in coronavirus disease 2019 (COVID-19), sponsored by GSK. Started May 2020; status: completed.
02
Drugs
otilimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04376684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376684.